It should be noted that off-target binding of the drug could lead to ADRs and may not be related to the same level of exposure that is responsible for on-target efficacy. Thus, an understanding of ...

The choice of the dose of an anticancer drug is established in first-in-human, dose-escalation, phase 1 clinical trials involving patients with cancer for whom standard-of-care treatments are often no ...

The World Health Organization’s (WHO) VigiAccess database lists adverse reactions (ADRs) reported by people after taking a drug or vaccine. It does not confirm that medicinal products or their active ...

For decades, the U.S. Food and Drug Administration's adverse events system has been the primary surveillance tool for monitoring potential side effects caused by drugs after they get on the market.